trending Market Intelligence /marketintelligence/en/news-insights/trending/qj04dFDT2Q-jV-NqRGsPfg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Zimmer Biomet's treatment for spine deformity gets US FDA approval

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Zimmer Biomet's treatment for spine deformity gets US FDA approval

Zimmer Biomet Holdings Inc. said the U.S. Food and Drug Administration approved its product — the Tether — to treat scoliosis, a type of spine deformity, in children.

Current treatment for scoliosis involves an invasive operation to attach metal rods, hooks, wires or screws on the spine to align the vertebrae. Tether is an anterior vertebral body tethering solution that uses a flexible cord instead of metal rods and is positioned using a minimally invasive procedure that requires few small openings between the ribs.

The treatment got clearance under the FDA's humanitarian device exemption pathway, which provides approval for products without requiring evidence of effectiveness.

Warsaw, Ind.-based healthcare equipment company Zimmer Biomet and the U.S. regulator will finalize a new clinical study to monitor the outcomes in patients treated with the Tether.